• MPM BioVentures 2014, a more-than-10% owner, reported sales of Entrada Therapeutics common stock from Sept. 1-3, 2026.
• Disposed of 86,482 shares at weighted-average prices of USD 7.06, USD 7.19, USD 7.17.
• Indirect beneficial ownership fell to 4,144,952 shares following the Sept. 3 transactions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Entrada Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001231919-26-001143), on September 03, 2026, and is solely responsible for the information contained therein.